Efficacy Study of ABR-215050 to Treat Prostate Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.

To investigate ABR-215050 as a possible treatment for prostate cancer.

Condition or disease

Intervention/treatment

Phase

Prostate Cancer

Drug: ABR-215050, tasquinimodDrug: Placebo

Phase 2

Detailed Description:

For asymptomatic patients with Castrate-Resistant Prostate Cancer (CRPC), a "window of opportunity" is present. During this "window of opportunity" an intervention with little or no toxicity and the potential for extending the "symptom-free" period would be of great value to keep metastatic patients in an asymptomatic stage and thus delay the introduction of chemotherapy. The purpose of this study is to evaluate the safety and efficacy of ABR-215050 as an interventional agent for this role.

Overall survival for patients participating in study 07TASQ08 will be evaluated retrospectively using a separate study protocol 11TASQ11.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:

18 Years and older (Adult, Senior)

Sexes Eligible for Study:

Male

Accepts Healthy Volunteers:

No

Criteria

Inclusion criteria:

Histologically confirmed diagnosis of adenocarcinoma of the prostate

Asymptomatic metastatic CRPC (VAS pain score less than or equal to 3). The patient may take non-opioid analgesics for non-cancer pain discomfort

Evidence of metastatic disease from CT or Bone scan

Evidence of progressive disease after castration levels of testosterone have been achieved defined by any of the following criteria:

Increased serum prostate-specific antigen (PSA) levels (Confirmed by 3 consecutive PSA measurements within 1 year with at least 14 days between each measurement)

Castrate levels of serum testosterone (less than or equal to 50 ng/dL or 1.7 nmol/L. Testosterone levels will not be required for patients who have had bilateral orchiectomy)

Karnofsky score 70-100

Laboratory values as follows:

Hb greater than or equal to 90g/L (greater than or equal to 9g/dL)

Serum creatinine less than or equal to 1.5 x upper limit of normal (ULN)

Total bilirubin less than or equal to 1.5 x ULN

AST (SGOT) / ALT (SGPT) less than or equal to 2.5 x ULN

Serum amylase less than or equal to ULN. (If serum amylase is greater than ULN, pancreatic amylase and serum lipase should be analyzed. If both pancreatic amylase and serum lipase is greater than ULN, exclude patient)

Patient if sexually active with partner of child bearing potential will agree to use adequate contraceptive methods (barrier contraceptive with spermicide or vasectomy) while on study drug

No evidence (greater than or equal to 5 years) of prior malignancies (except successfully treated basal cell, squamous cell carcinoma of the skin)

Ability to administer and retain oral medication

Able to adhere to the study visit schedule and other protocol requirements

Exclusion criteria:

Prior cytotoxic chemotherapy within 3 years

Previous anti-cancer therapy using biologics or vaccines within the last 6 months. Previous treatment with bevacizumab is not allowed.

Any treatment modalities, involving radiation and surgery, not discontinued at least 4 weeks prior to treatment in this study

Any condition, including the presence of laboratory abnormalities, which confounds the ability to interpret data from the study or places the patient at unacceptable risk if he participates in the study

Concurrent use of other anti-cancer agents or treatments [a stable dose of LHRH agonists, bicalutamide (e.g. Casodex) and/or other antiandrogens is allowed]

Known brain metastases

Simultaneous participation in any other study involving investigational drugs or having participated in a study less than 4 weeks prior to start of study treatment

Exposure to ketoconazole or other strong CYP3A4 inhibitors or inducers intravenously or orally within 14 days prior to inclusion

Known positive serology for HIV (patients with known history of HIV will be excluded because of potential for unforeseen toxicity and morbidity in an immunocompromised host)

Chronic hepatitis with advanced, decompensated hepatic disease or cirrhosis of the liver or history of a chronic virus hepatitis or known viral hepatitis carrier (patients recovered from hepatitis will be allowed to enter the study)